Ignite Creation Date:
2025-12-25 @ 2:44 AM
Ignite Modification Date:
2026-06-21 @ 10:15 PM
Study NCT ID:
NCT06048133
Status:
RECRUITING
Last Update Posted:
2025-05-04
First Post:
2023-09-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Sponsor:
Nataliya Uboha
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
BTCRC-GI22-564
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None